Bone marrow transplantation for sickle cell disease.
暂无分享,去创建一个
J. Scott | K. Sullivan | R. Storb | W. Leisenring | J. Eckman | S. Davies | W. Mentzer | F. Bernaudin | M. Walters | D. Matthews | K. Ohene‐Frempong | M. Patience | S. Davies
[1] J. Scott,et al. Barriers to bone marrow transplantation for sickle cell anemia. , 1996, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] M. Andreani,et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. , 1996, Blood.
[3] A. Nagler,et al. Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation. , 1995, Blood.
[4] F. Appelbaum,et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. , 1995, Bone marrow transplantation.
[5] M L Terrin,et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.
[6] K. Sullivan,et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. , 1995, Blood.
[7] E. Vichinsky,et al. Effects of a long-term transfusion regimen on sickle cell-related illnesses. , 1994, The Journal of pediatrics.
[8] C. Vermylen,et al. Bone marrow transplantation for sickle cell disease. The European experience. , 1994, The American journal of pediatric hematology/oncology.
[9] K. Sullivan,et al. Bone marrow transplantation for sickle cell disease. The United States experience. , 1994, The American journal of pediatric hematology/oncology.
[10] A. Nademanee,et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. , 1993, The New England journal of medicine.
[11] M. Andreani,et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. , 1993, The New England journal of medicine.
[12] S. Lemerle,et al. Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO. , 1993, Bone marrow transplantation.
[13] G. Koren,et al. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients. , 1993, Bone marrow transplantation.
[14] R. Smith. Using a mock trial to make a difficult clinical decision. , 1992, BMJ.
[15] M. Andreani,et al. Mixed chimerism in thalassemic patients after bone marrow transplantation. , 1992, Bone marrow transplantation.
[16] E. Sariban,et al. Bone marrow transplantation for severe sickle cell anaemia , 1992, British journal of haematology.
[17] C. Stocking,et al. Bone marrow transplantation for sickle cell disease. A study of parents' decisions. , 1991, The New England journal of medicine.
[18] J. Niland,et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. , 1991, Annals of internal medicine.
[19] S. Piomelli. Sickle cell diseases in the 1990s: the need for active and preventive intervention. , 1991, Seminars in hematology.
[20] E. Vichinsky. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. , 1991, Seminars in hematology.
[21] K. Sullivan,et al. Introduction to a symposium on sickle cell anemia: current results of comprehensive care and the evolving role of bone marrow transplantation. , 1991, Seminars in hematology.
[22] R. Mulhern,et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. , 1991, The Journal of pediatrics.
[23] G. Lucarelli,et al. Bone marrow transplantation in patients with thalassemia. , 1990, The New England journal of medicine.
[24] S. Leikin,et al. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. , 1989, Pediatrics.
[25] M. Dyer,et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. , 1989, Blood.
[26] K. Sullivan,et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. , 1989, The New England journal of medicine.
[27] C. Vermylen,et al. BONE MARROW TRANSPLANTATION IN FIVE CHILDREN WITH SICKLE CELL ANAEMIA , 1988, The Lancet.
[28] J. Niland,et al. Sickle Cell Chronic Lung Disease: Prior Morbidity and the Risk of Pulmonary Failure , 1988, Medicine.
[29] R. Parkman. The application of bone marrow transplantation to the treatment of genetic diseases. , 1986, Science.
[30] N. Flournoy,et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. , 1986, The New England journal of medicine.
[31] H. Deeg,et al. Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty "untransfused" patients. , 1986, Annals of internal medicine.
[32] H. Deeg,et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.
[33] A. Look,et al. Bone-marrow transplantation in a patient with sickle-cell anemia. , 1984, The New England journal of medicine.
[34] W. Schroeder,et al. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? , 1984, Blood.
[35] J. Clegg,et al. The interaction of alpha-thalassemia and homozygous sickle-cell disease. , 1982, The New England journal of medicine.
[36] R. Storb,et al. Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis. , 1982 .
[37] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[38] D. Powars. Natural history of sickle cell disease--the first ten years. , 1975, Seminars in hematology.
[39] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .